Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics.

International journal of molecular sciences - 9 Dec 2024

Rane Shraddha S, Elyoussfi Sarah, Shellard Elan, Eyre Steve, Warren Richard B

Abstract excerpt

Psoriasis (Ps) is a debilitating immune-mediated chronic skin condition. It affects about 1-3% of the world population, with an 8-11% prevalence in Northern European populations. Tyrosine kinase 2 (TYK2) is a newly identified target for Ps. An independent non-coding genetic association with Ps has been identified ~400 kb upstream of TYK2. The variants making up the credible Ps Single-Nucleotide Polymorphism (SNP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to Gene Expression Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Genomics

Share to Jurkat Cells

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 39684939
DOI: 10.3390/ijms252313229
PMCID: PMC11642893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics.PMID 39684939Read ↗

Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization.Semantic proximity Read ↗

Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31.Semantic proximity Read ↗

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.Semantic proximity Read ↗

The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cellsSemantic proximity Read ↗

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.Semantic proximity Read ↗

Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesSemantic proximity Read ↗

Chromatin-based techniques map DNA interaction landscapes in psoriasis susceptibility loci and highlight <i>KLF4</i> as a target gene in 9q31Semantic proximity Read ↗

TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.Semantic proximity Read ↗

Functional Genomics in Psoriasis.Semantic proximity Read ↗

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.Semantic proximity Read ↗

A catalog of potential putative functional variants in psoriasis genome-wide association regions.Semantic proximity Read ↗

Genetically proxied TYK2 inhibition is associated with reduced sarcoidosis susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.